Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 9/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617926 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL313779 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL11173165 | 0.91 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL1846647 | 0.91 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL2531297 | 0.91 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL15214454 | 0.87 | KLK5 (0.41) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL800751 | 0.87 | KMT2A (0.44) | CYP2C9CYP2C19CTSKCTSSCA1 | |
| SCHEMBL12555978 | 0.87 | KMT2A (0.44) | CYP2C9CYP2C19CTSKCTSSCA1 | |
| SCHEMBL2555252 | 0.87 | KMT2A (0.44) | CYP2C9CYP2C19CTSKCTSSCA1 | |
| SCHEMBL18220550 | 0.87 | KMT2A (0.44) | CYP2C9CYP2C19CTSKCTSSCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 580 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025261-A | Synthesis method of 2-aminoacyl substituted L-phenylalanine | 康化（上海）新药研发有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-120004764-A | Preparation method of amino acid tert-butyl ether | 四川什邡市三高生化实业有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-118772027-A | Preparation method of L-selenium-methyl selenocysteine | 江苏惠利生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118108576-A | Method for removing tetrahydropyran protecting groups on alcohols and phenols | 南京工业大学 | 2024-05-31 | — | — | CN | claimed |
| CN-118026866-A | Synthesis of 4-chlorokynurenine and intermediates | 维斯塔津治疗公司 | 2024-05-14 | — | — | CN | claimed |
| CN-112236412-B | Synthesis of 4-chlorokynurenine and intermediates | 维斯塔津治疗公司 | 2024-01-30 | — | — | CN | claimed |
| CN-116903552-A | Chiral alpha-amino alcohol compound and preparation method and application thereof | 上海大学 | 2023-10-20 | — | — | CN | claimed |
| EP-3749638-B1 | SYNTHESIS OF 4-CHLOROKYNURENINES AND INTERMEDIATES | VISTAGEN THERAPEUTICS INC (US) | 2023-04-05 | — | — | EP | claimed |
| US-11427530-B2 | Synthesis of 4-chlorokynurenines and intermediates | VISTAGEN THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | claimed |
| CN-111909067-B | Organic total synthesis method of D-penicillamine | 浙江凯普化工有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-111909067-A | Organic total synthesis method of D-penicillamine | 浙江凯普化工有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-108047268-B | 1-aza-5-gera-5-alkyl bicyclo [3.3.3] undecane compound, synthesis method and application | 中国科学技术大学 | 2020-05-01 | — | — | CN | claimed |
| CN-105209439-A | Process for manufacture of gadofosveset trisodium monohydrate | LANTHEUS MEDICAL IMAGING INC | 2015-12-30 | — | — | CN | claimed |
| CN-103601706-B | Method for synthesizing natural product Jaspine B isomer | UNIV JIANGXI NORMAL SCI & TECH | 2015-07-01 | — | — | CN | claimed |
| CN-103601706-A | Method for synthesizing natural product Jaspine B isomer | UNIV JIANGXI NORMAL SCI & TECH | 2014-02-26 | — | — | CN | claimed |
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-4652676-A | L-aminodicarboxylic acid alkenes | GENERAL FOODS CORPORATION (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0201844-A1 | L-Aminodicarboxylic acid alkenes and an edible composition containing same | GENERAL FOODS CORPORATION (US) | 1986-11-20 | — | — | EP | disclosed |
| US-4401658-A | VACCINE ADJUVANTS, IMMUNOSTIMULANTS | RHONE-POULENC SANTE (FR) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | CYP1A2 1927/4885CYP2C9 853/4885CYP2C19 1032/4885 |
| US-11427530-B2 | Synthesis of 4-chlorokynurenines and intermediates | KMO, KYNU, AADAT | CYP1A2 119/4885CYP2C9 120/4885CYP2C19 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.